Home/Indications/Immunology/Atopic Dermatitis

Atopic Dermatitis

Immunology 6 original drugs

Novel Drugs

Reformulations

Drug Targets

Immunology indication. Atopic Dermatitis has 6 FDA-approved novel treatments, led by Pfizer, with 168 active industry clinical trials across 10 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Atopic Dermatitis Market Leaders

Companies with the most FDA-approved novel Atopic Dermatitis drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Ruxolitinib

Incyte Corporation

Estimated · aging NCT06832618

Q3 2026

CM310

Keymed Biosciences Co.Ltd

Estimated · aging NCT06495229

Q3 2026

Upadacitinib 15mg Dose

AbbVie

Estimated · fresh NCT06389136

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Atopic Dermatitis Treatments by Mechanism

Top 12 mechanisms across 68 industry trials with a known mechanism of action.

See full pipeline →

Janus Kinase Inhibitor

24 trials 6 active 4 sponsors

Interleukin-4 Receptor alpha Antagonist

22 trials 2 active 4 sponsors

Folate Analog Metabolic Inhibitor

1 trials 1 active 1 sponsor

Interleukin-13 Antagonist

12 trials 1 sponsor

Phosphodiesterase 4 Inhibitor

2 trials 2 sponsors

Glucocorticoid receptor

1 trials 1 sponsor

Calcineurin/FKBP-12

1 trials 1 sponsor

Retinoid

1 trials 1 sponsor

JAK1/JAK2/JAK3/TYK2

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

Interleukin-5 Receptor alpha-directed Cytolytic Antibody

1 trials 1 sponsor

Anti-IgE

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Atopic Dermatitis Clinical Pipeline by Phase

579 industry-sponsored trials across 215 sponsors

View full landscape →

Showing 19 of 19 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	Lebrikizumab	—	ACTIVE NOT RECRUITING	2026-05-14	NCT07006792
Integrative Skin Science and Research	Roflumilast Cream 0.15%	—	NOT YET RECRUITING	2027-08	NCT07560618
Regeneron	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2024-11-14	NCT05590585
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2024-07-11	NCT05507580
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2024-01-25	NCT05624112
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2023-12-22	NCT05680298
Libbs Farmacêutica LTDA	Mometasone Furoate	Glucocorticoid receptor	COMPLETED	2023-07-10	NCT04271007
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2021-10-06	NCT04033367
Sanofi	Dupilumab SAR231893	—	COMPLETED	2021-06-17	NCT04447417
Pfizer	Crisaborole ointment 2%	—	COMPLETED	2019-04-12	NCT03356977
Haus Bioceuticals	HAT1	—	COMPLETED	2016-06-26	NCT03406117
Procter & Gamble Beauty	Investigational OTC Cream	—	COMPLETED	2016-06	NCT02732314
Astellas	tacrolimus	Calcineurin/FKBP-12	COMPLETED	2013-11	NCT01745159
Max Zeller Soehne AG	EPOGAM 1000	—	COMPLETED	2010-10	NCT00878670
Promius Pharma, LLC	Desonide Cream 0.05%	—	COMPLETED	2009-08	NCT00828412
Incyte Corporation	ruxolitinib cream	—	TERMINATED	2025-01-22	NCT05696392
Pfizer	Crisaborole ointment, 2%	—	TERMINATED	2020-12-11	NCT03539601
Regeneron	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	WITHDRAWN	2027-12-23	NCT07187089
LEO Pharma	Cyclosporine A	—	WITHDRAWN	2020-08	NCT03710044

Showing 100 of 162 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Upadacitinib 15mg Dose	—	RECRUITING	2026-08	NCT06389136
LEO Pharma	Tralokinumab + TCS	—	RECRUITING	2026-10-20	NCT06311682
medac GmbH	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	RECRUITING	2026-11	NCT06239311
Beijing InnoCare Pharma Tech Co., Ltd.	ICP-332 Tablets	—	RECRUITING	2026-11-25	NCT06775860
Qilu Pharmaceutical Co., Ltd.	1.5% QLM3003 ointment	—	RECRUITING	2027-03	NCT06880276
Pfizer	Abrocitinib	Janus Kinase Inhibitor [EPC]	RECRUITING	2027-05-02	NCT06807268
Jiangsu vcare pharmaceutical technology co., LTD	VC005 low dose group	—	RECRUITING	2027-08-30	NCT06723080
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819 Injection	—	RECRUITING	2027-11	NCT07309055
Organon and Co	Tapinarof cream, 1%	—	RECRUITING	2028-01	NCT07265479
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	RECRUITING	2030-07	NCT06461897
Pfizer	Abrocitinib	Janus Kinase Inhibitor [EPC]	RECRUITING	2032-02-22	NCT06807281
Prime Gene Therapeutics Co., Ltd.	PG-011Gel	—	RECRUITING	2024-11-19	NCT06587685
Incyte Corporation	Ruxolitinib	—	ACTIVE NOT RECRUITING	2026-07-13	NCT06832618
Keymed Biosciences Co.Ltd	CM310	—	ACTIVE NOT RECRUITING	2026-08-30	NCT06495229
Galderma R&D	Nemolizumab	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03989206
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	ACTIVE NOT RECRUITING	2026-10-07	NCT02612454
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-01	NCT06701331
Almirall, S.A.	Lebrikizumab	—	ACTIVE NOT RECRUITING	2027-04-25	NCT06526182
Amgen	Rocatinlimab	—	ACTIVE NOT RECRUITING	2026-06-22	NCT05882877
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Jaktinib Hydrochloride Tablet	—	ACTIVE NOT RECRUITING	2026-06	NCT05526222
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819	—	ACTIVE NOT RECRUITING	2026-03-31	NCT06468956
Eli Lilly	Lebrikizumab	—	ACTIVE NOT RECRUITING	2026-01-14	NCT05559359
Eli Lilly	Lebrikizumab	—	ACTIVE NOT RECRUITING	2025-09-25	NCT06280716
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQH2722 injection	—	ACTIVE NOT RECRUITING	2025-09-11	NCT06552520
Almirall, S.A.	Lebrikizumab	—	ACTIVE NOT RECRUITING	2025-06-23	NCT05990725
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2022-04-24	NCT03952559
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-02-16	NCT03568318
Otsuka Pharmaceutical Co., Ltd.	OPA-15406	—	NOT YET RECRUITING	2026-12	NCT07173478
Otsuka Pharmaceutical Co., Ltd.	OPA-15406	—	NOT YET RECRUITING	2027-02	NCT07184645
Keymed Biosciences Co.Ltd	Stapokibatrt	—	NOT YET RECRUITING	2027-02	NCT07106372
Jiangsu Genscend Biopharmaceutical Co., Ltd	GS101 injection	—	NOT YET RECRUITING	2027-04	NCT07386743
Qilu Pharmaceutical Co., Ltd.	QL2108 injection	—	NOT YET RECRUITING	2027-05	NCT06884891
Akeso	Placebo	—	NOT YET RECRUITING	2027-07-10	NCT06767540
Shanghai Longwood Biopharmaceuticals Co., Ltd.	LW402	—	NOT YET RECRUITING	2028-03-31	NCT07370909
Jiangsu vcare pharmaceutical technology co., LTD	VC005	—	NOT YET RECRUITING	2028-05-30	NCT07592585
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10 Humanized Monoclonal Antibody Injection	—	NOT YET RECRUITING	2029-01	NCT07479615
EHL Bio Co., Ltd.	ADSTEM Inj.	—	NOT YET RECRUITING	2029-06	NCT07377838
Keymed Biosciences Co.Ltd	Stapokibatrt	—	NOT YET RECRUITING	2026-05	NCT06956196
Almirall, S.A.	Lebrikizumab	—	COMPLETED	2026-04-23	NCT05916365
Amgen	Rocatinlimab	—	COMPLETED	2025-07-31	NCT05633355
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Roflumilast Cream 0.15%	—	COMPLETED	2025-05-27	NCT06631170
Incyte Corporation	Ruxolitinib Cream	—	COMPLETED	2025-05-21	NCT06238817
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2025-05-05	NCT05958407
Lynk Pharmaceuticals Co., Ltd	LNK01001	—	COMPLETED	2025-04-18	NCT06277245
Amgen	—	—	COMPLETED	2025-04-11	NCT06224192
Amgen	Rocatinlimab	—	COMPLETED	2025-02-27	NCT05704738
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2025-01-23	NCT06277765
Minghui Pharmaceutical (Hangzhou) Ltd	MH004 Ointment	—	COMPLETED	2024-12-13	NCT07185282
Amgen	Rocatinlimab	—	COMPLETED	2024-11-28	NCT05398445
Amgen	Rocatinlimab	—	COMPLETED	2024-09-15	NCT05724199
Amgen	Rocatinlimab	—	COMPLETED	2024-08-26	NCT05899816
Acrotech Biopharma Inc.	Difamilast	—	COMPLETED	2024-07-31	NCT05571943
Otsuka Beijing Research Institute	0.3% OPA-15406 Ointment	—	COMPLETED	2024-07-21	NCT05650320
Eli Lilly	Lebrikizumab	—	COMPLETED	2024-07-19	NCT04392154
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2024-07-03	NCT03587805
Otsuka Beijing Research Institute	1% OPA-15406 Ointment	—	COMPLETED	2024-06-17	NCT05667623
Eli Lilly	Lebrikizumab Pen	—	COMPLETED	2024-06-10	NCT06444165
Amgen	Rocatinlimab	—	COMPLETED	2024-06-05	NCT05651711
Arcutis Biotherapeutics, Inc.	ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	—	COMPLETED	2024-05-28	NCT04804605
Incyte Corporation	Ruxolitinib Cream	—	COMPLETED	2024-05-17	NCT05456529
Eli Lilly	Lebrikizumab	—	COMPLETED	2024-05-03	NCT05372419
AbbVie	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2024-03-19	NCT05601882
Organon and Co	Tapinarof cream, 1%	—	COMPLETED	2024-02-29	NCT05142774
Eli Lilly	Lebrikizumab	—	COMPLETED	2024-01-11	NCT05369403
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2023-10-31	NCT05265923
Acrotech Biopharma Inc.	Difamilast	—	COMPLETED	2023-10-27	NCT05608343
Catalysis SL	—	—	COMPLETED	2023-09-15	NCT06361992
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2023-09-11	NCT04195698
Pfizer	Abrocitinib 100 mg	—	COMPLETED	2023-06-09	NCT05375929
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2023-06-06	NCT05194540
Arcutis Biotherapeutics, Inc.	Roflumilast Cream 0.05%	—	COMPLETED	2023-06-01	NCT04845620
Incyte Corporation	Ruxolitinib	—	COMPLETED	2023-05-10	NCT04921969
Organon and Co	tapinarof cream, 1%	—	COMPLETED	2023-03-30	NCT05014568
Organon and Co	tapinarof cream, 1%	—	COMPLETED	2023-02-03	NCT05032859
Almirall, S.A.	Lebrikizumab	—	COMPLETED	2023-01-30	NCT05149313
Otsuka Pharmaceutical Co., Ltd.	OPA-15406	—	COMPLETED	2022-12-29	NCT05372653
Arcutis Biotherapeutics, Inc.	Roflumilast Cream	—	COMPLETED	2022-09-29	NCT04773600
Arcutis Biotherapeutics, Inc.	Roflumilast Cream 0.15%	—	COMPLETED	2022-08-30	NCT04773587
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2022-08-19	NCT03661138
Reistone Biopharma Company Limited	Core Treatment Active Experimental: SHR0302 Dose#1	—	COMPLETED	2022-08-12	NCT04875169
Eli Lilly	Lebrikizumab	—	COMPLETED	2022-08-03	NCT04626297
Eli Lilly	Lebrikizumab	—	COMPLETED	2022-07-31	NCT04760314
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2022-06-27	NCT01949311
Eli Lilly	Lebrikizumab	—	COMPLETED	2022-04-20	NCT04250350
Galderma R&D	Nemolizumab	—	COMPLETED	2022-02-23	NCT03989349
Pfizer	Crisaborole 2%	—	COMPLETED	2022-01-19	NCT04040192
Galderma R&D	Nemolizumab	—	COMPLETED	2021-12-29	NCT03985943
Sanofi	Dupilumab SAR231893	—	COMPLETED	2021-12-14	NCT04678882
Pfizer	Crisaborole Ointment	—	COMPLETED	2021-09-08	NCT04360187
Eli Lilly	Lebrikizumab	—	COMPLETED	2021-08-11	NCT04250337
Pfizer	Abrocitinib 200 mg	—	COMPLETED	2021-07-13	NCT04345367
Eli Lilly	Lebrikizumab	—	COMPLETED	2021-07-12	NCT04178967
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2021-07-06	NCT04587453
Eli Lilly	Lebrikizumab	—	COMPLETED	2021-06-21	NCT04146363
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-03-11	NCT03607422
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-01-06	NCT03569293
Otsuka Pharmaceutical Co., Ltd.	0.3% OPA-15406 ointment	—	COMPLETED	2020-11-11	NCT03961529
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2020-09-21	NCT03334435
Pfizer	PF-04965842 100 mg	—	COMPLETED	2020-09-02	NCT03627767
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2020-08-27	NCT03738397

Showing 100 of 283 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Keymed Biosciences Co.Ltd	CM512	—	RECRUITING	2026-07-18	NCT06947980
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1905 Injection	—	RECRUITING	2026-09	NCT07211542
Pfizer	PF-07275315	—	RECRUITING	2026-10-19	NCT05995964
Enveda Therapeutics	ENV-294	—	RECRUITING	2026-12	NCT07298395
AbbVie	Lutikizumab	—	RECRUITING	2027-02	NCT06524635
Bluefin Biomedicine, Inc.	BFB759	—	RECRUITING	2027-02-28	NCT07105488
Innovent Biologics (Suzhou) Co. Ltd.	IBI3002	—	RECRUITING	2027-03-23	NCT07399067
SinoMab BioScience Ltd	SM17 for subcutaneous injection	—	RECRUITING	2027-04-25	NCT07445919
UCB Biopharma SRL	Galvokimig	—	RECRUITING	2027-05-17	NCT07277660
Oneness Biotech Co., Ltd.	FB825	—	RECRUITING	2027-05-31	NCT06397911
Kymera Therapeutics, Inc.	KT-621	—	RECRUITING	2027-06	NCT07217015
Corvus Pharmaceuticals, Inc.	Soquelitinib	—	RECRUITING	2027-06	NCT07441395
Innovent Biologics (Suzhou) Co. Ltd.	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	RECRUITING	2027-06-30	NCT07330934
Hangzhou Highlightll Pharmaceutical Co., Ltd	HL-300	—	RECRUITING	2027-06-30	NCT07629778
Apollo Therapeutics Ltd	Camoteskimab	—	RECRUITING	2027-10-31	NCT07599813
Inmagene LLC	IMG-007	—	RECRUITING	2027-12	NCT07037901
Keymed Biosciences Co.Ltd	CM512	—	RECRUITING	2027-12	NCT07230483
Chengdu Zenitar Biomedical Technology Co., Ltd	The high-dose group of ZL-82 tablets	—	RECRUITING	2027-12-30	NCT07193589
Pfizer	PF-08049820	—	RECRUITING	2028-02-02	NCT07216027
Novartis	GHZ339	—	RECRUITING	2028-11-27	NCT06947993
Apogee Therapeutics, Inc.	APG777	—	RECRUITING	2029-12	NCT07003425
Roche	Afimkibart	—	RECRUITING	2033-03-01	NCT07223697
Turn Therapeutics	—	—	RECRUITING	2026-07-10	NCT07355075
Alphyn Biologics	zabalafin	—	RECRUITING	2025-10-30	NCT06855745
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819 injection	—	RECRUITING	2025-09	NCT06713499
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10	—	RECRUITING	2025-05	NCT06765005
Roche	Afimkibart	—	ACTIVE NOT RECRUITING	2026-07-22	NCT06863961
Aclaris Therapeutics, Inc.	ATI-045	—	ACTIVE NOT RECRUITING	2026-08	NCT07011706
Triveni Bio	TRIV-509	—	ACTIVE NOT RECRUITING	2026-10	NCT07167758
Apogee Therapeutics, Inc.	APG777	—	ACTIVE NOT RECRUITING	2026-11	NCT06395948
AbbVie	Lutikizumab	—	ACTIVE NOT RECRUITING	2027-05	NCT06718101
Novartis	GIA632	—	ACTIVE NOT RECRUITING	2027-05-17	NCT07220577
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819 Injection	—	ACTIVE NOT RECRUITING	2027-06	NCT07321951
Celldex Therapeutics	Barzolvolimab	—	ACTIVE NOT RECRUITING	2026-05	NCT06727552
Xizang Haisco Pharmaceutical Co., Ltd	HSK44459	—	ACTIVE NOT RECRUITING	2026-01-20	NCT06996912
Nektar Therapeutics	Rezpegaldesleukin	—	ACTIVE NOT RECRUITING	2025-05-06	NCT06136741
Tavotek Biotherapeutics	TAVO101	—	ACTIVE NOT RECRUITING	2025-03-15	NCT06176040
Q32 Bio Inc.	ADX-914	—	ACTIVE NOT RECRUITING	2024-12	NCT05509023
EHL Bio Co., Ltd.	ADSTEM Inj.	—	ACTIVE NOT RECRUITING	2023-01-26	NCT04137562
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0278 injection	—	NOT YET RECRUITING	2026-08-15	NCT07175233
HK inno.N Corporation	IN-115314 Ointment 1%	—	NOT YET RECRUITING	2026-09-30	NCT07073677
Enzychem Lifesciences Corporation	EC-18	—	NOT YET RECRUITING	2026-10	NCT06487000
Dermavon Holdings Limited	CMS-D001 50mg	—	NOT YET RECRUITING	2027-01-31	NCT07465120
Jiangsu vcare pharmaceutical technology co., LTD	VC005 group	—	NOT YET RECRUITING	2027-02-22	NCT07598383
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10 placebo	—	NOT YET RECRUITING	2027-07-16	NCT07103174
Qilu Pharmaceutical Co., Ltd.	QLS12010	—	NOT YET RECRUITING	2027-09	NCT07344051
Akeso	AK139	—	NOT YET RECRUITING	2027-11	NCT07502222
Enveda Therapeutics	ENV-294	—	NOT YET RECRUITING	2027-12	NCT07643766
Galderma R&D	Nemolizumab	—	NOT YET RECRUITING	2028-07-15	NCT07660835
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.	LT-002-158 tablets	—	NOT YET RECRUITING	2025-10-30	NCT06931990
Zhejiang Kanova Biopharmaceutical Co., LTD	XKH001 Injection	—	NOT YET RECRUITING	2025-10-01	NCT07054736
Akeso	AK120	—	NOT YET RECRUITING	2025-06-30	NCT06756126
Shaperon	HY209GEL Active	—	COMPLETED	2026-04-13	NCT06024499
Reistone Biopharma Company Limited	RSS0393 ointment	—	COMPLETED	2026-04-10	NCT07158151
Arcutis Biotherapeutics, Inc.	ARQ-151 cream 0.05%	—	COMPLETED	2025-12-04	NCT06998056
Hangzhou Yirui Pharmaceutical Technology Co., Ltd	YR001 ointment	—	COMPLETED	2025-11-20	NCT06309355
Evommune, Inc.	EVO301	—	COMPLETED	2025-11-17	NCT06723405
Jiangsu vcare pharmaceutical technology co., LTD	VC005 groups	—	COMPLETED	2025-10-31	NCT06891040
CAGE Bio Inc.	CGB-500 with 0.5% tofacitinib	—	COMPLETED	2025-08-30	NCT06810050
Akeso	AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)	—	COMPLETED	2025-07-31	NCT06700499
CAGE Bio Inc.	CGB-500 Ointment with 1% tofacitinib	—	COMPLETED	2025-07-30	NCT06923228
Lynk Pharmaceuticals Co., Ltd	LNK01004 ointment 0.3%	—	COMPLETED	2025-07-24	NCT07071610
UCB Biopharma SRL	UCB1381	—	COMPLETED	2025-07-17	NCT05277571
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-1819 injection	—	COMPLETED	2025-06-05	NCT06012812
Galderma R&D	Nemolizumab	—	COMPLETED	2025-04-28	NCT04921345
Apollo Therapeutics Ltd	Camoteskimab	—	COMPLETED	2025-03-26	NCT06436183
Aclaris Therapeutics, Inc.	ATI-2138	—	COMPLETED	2025-03-13	NCT06585202
Technoderma Medicines Inc.	TDM-180935 topical ointment 1.0%	—	COMPLETED	2025-03-08	NCT06363461
Xantho Biotechnology Co., LTD	GM-XANTHO onitment	—	COMPLETED	2025-01-22	NCT04369846
LEO Pharma	LEO 138559	—	COMPLETED	2024-12-11	NCT05923099
Siolta Therapeutics, Inc.	STMC-103H	—	COMPLETED	2024-11-26	NCT05003804
Akeso	AK120	—	COMPLETED	2024-11-13	NCT06092762
Shanghai Longwood Biopharmaceuticals Co., Ltd.	LW402	—	COMPLETED	2024-09-25	NCT07186387
Biosion, Inc.	BSI-045B	—	COMPLETED	2024-09-18	NCT05932654
Qilu Pharmaceutical Co., Ltd.	1.5% QLM3003	—	COMPLETED	2024-09-02	NCT06058000
Escient Pharmaceuticals, Inc	Oral EP262	—	COMPLETED	2024-07-31	NCT06144424
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2024-07-18	NCT05715320
Jiangsu vcare pharmaceutical technology co., LTD	VC005 tablets	—	COMPLETED	2024-07-09	NCT05997927
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2024-07-04	NCT06162507
Akeso	AK120	—	COMPLETED	2024-06-21	NCT06035354
UCB Biopharma SRL	UCB9741	—	COMPLETED	2024-04-23	NCT04643457
Ganzhou Hemay Pharmaceutical Co., Ltd	Hemay005	—	COMPLETED	2024-01-24	NCT05769946
UNION therapeutics	Orismilast modified release tablets	—	COMPLETED	2024-01-23	NCT05469464
Bayer	Zabedosertib (BAY1834845)	—	COMPLETED	2024-01-03	NCT05656911
Amytrx Therapeutics, Inc.	1.1% w/w AMTX-100 CF-part1	—	COMPLETED	2023-12-19	NCT04313400
Aldeyra Therapeutics, Inc.	ADX-629 (Open-label)	—	COMPLETED	2023-11-21	NCT05717920
Aclaris Therapeutics, Inc.	ATI-1777 2.0% w/w	—	COMPLETED	2023-10-26	NCT05432596
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2023-10-20	NCT05388760
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-1819	—	COMPLETED	2023-09-15	NCT05549947
Incyte Corporation	Ruxolitinib cream	—	COMPLETED	2023-08-03	NCT05127421
Pfizer	PF-07038124 ointment 0.01%	—	COMPLETED	2023-07-31	NCT05375955
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2023-07-28	NCT05579925
Evommune, Inc.	EVO101	—	COMPLETED	2023-07-27	NCT05579899
JW Pharmaceutical	LEO 152020 tablet	—	COMPLETED	2023-07-20	NCT05117060
CAGE Bio Inc.	Tofacitinib Citrate	JAK1/JAK2/JAK3/TYK2	COMPLETED	2023-06-30	NCT05487963
Sanofi	Rilzabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2023-06-23	NCT05018806
Lynk Pharmaceuticals Co., Ltd	LNK01001 Dose A	—	COMPLETED	2023-06-14	NCT06085521
LEO Pharma	LEO 138559	—	COMPLETED	2023-06-07	NCT05470114
Galderma R&D	Nemolizumab	—	COMPLETED	2023-06-07	NCT04562116
Kymab Limited	Amlitelimab	—	COMPLETED	2023-04-26	NCT05131477

Showing 100 of 115 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bambusa Therapeutics	BBT001	—	RECRUITING	2026-08-21	NCT06808477
Sitryx Therapeutics Ltd	SYX-5219 Oral Capsule	—	RECRUITING	2026-08-30	NCT07558668
Bambusa Therapeutics	BBT001	—	RECRUITING	2026-08-31	NCT07239947
Jiangsu Genscend Biopharmaceutical Co., Ltd	GS101 injection	—	RECRUITING	2026-09	NCT07411755
Chong Kun Dang Pharmaceutical	CKD-706	—	RECRUITING	2026-11-16	NCT07358156
Pfizer	PF-07832837	—	RECRUITING	2027-06-02	NCT06564389
Seismic Therapeutic AU Pty Ltd	S-4321	—	RECRUITING	2027-09	NCT07455578
TRex Bio, Inc.	TRB-061	—	RECRUITING	2027-09-02	NCT06934252
Zai Lab (Shanghai) Co., Ltd.	ZL-1503	—	RECRUITING	2027-12-28	NCT07235384
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB575 Injection/SKB575 Placebo	—	RECRUITING	2027-12-31	NCT07488065
Arcutis Biotherapeutics, Inc.	ARQ-234	—	RECRUITING	2028-04	NCT07453602
Regeneron	REGN20423	—	RECRUITING	2028-06-23	NCT07527923
Brexogen Inc.	BxC-I17e (primed iMSC derived Extracellular vesicles(EV))	—	RECRUITING	2026-03-31	NCT06055361
LAPIX Therapeutics Inc.	LPX-TI641	—	RECRUITING	2026-01-15	NCT06982352
Shanghai Qilu Pharmaceutical Research and Development Center LTD	QLS12010	—	RECRUITING	2025-12	NCT06946641
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.	LT-002-158/Placebo oral tablet(s)	—	RECRUITING	2025-03-31	NCT06082323
Generate Biomedicines	GB-7624	—	ACTIVE NOT RECRUITING	2026-08-30	NCT06920693
Attovia Therapeutics Inc	ATTO-3712	—	ACTIVE NOT RECRUITING	2026-10	NCT07205081
Apogee Therapeutics, Inc.	APG777	—	ACTIVE NOT RECRUITING	2026-12	NCT07027527
Attovia Therapeutics Inc	ATTO-1310	—	ACTIVE NOT RECRUITING	2026-05	NCT06787586
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819 Injection	—	ACTIVE NOT RECRUITING	2026-04	NCT07264335
Pfizer	PF-08049820	—	ACTIVE NOT RECRUITING	2025-12-15	NCT07190430
Innovent Biologics (Suzhou) Co. Ltd.	IBI3033	—	NOT YET RECRUITING	2027-02-10	NCT07549984
Helixon Biotechnology (Suzhou) Co., Ltd	HXN5003	—	NOT YET RECRUITING	2027-03-18	NCT07549750
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	new formulations of 611	—	NOT YET RECRUITING	2026-01	NCT07042113
BeiGene	BGB-45035	—	COMPLETED	2026-06-02	NCT06342713
Jiangsu vcare pharmaceutical technology co., LTD	VC005 Tablets	—	COMPLETED	2026-04-30	NCT07533851
Jiangsu vcare pharmaceutical technology co., LTD	VC005	—	COMPLETED	2026-02-06	NCT07329101
SinoMab BioScience Ltd	SM17	—	COMPLETED	2026-02-03	NCT07466940
Corvus Pharmaceuticals, Inc.	Soquelitinib	—	COMPLETED	2026-01-28	NCT06345404
Enveda Therapeutics	ENV-294 Capsule	—	COMPLETED	2026-01-13	NCT07336940
Kymera Therapeutics, Inc.	KT-621	—	COMPLETED	2025-11-10	NCT06945458
Pfizer	PF-08049820 MR1	—	COMPLETED	2025-10-04	NCT07172321
Keymed Biosciences Co.Ltd	CM512	—	COMPLETED	2025-08-26	NCT06553209
Innovent Biologics (Suzhou) Co. Ltd.	IBI356 for MAD	—	COMPLETED	2025-08-20	NCT06193434
Jiangsu vcare pharmaceutical technology co., LTD	[14C]VC005	—	COMPLETED	2025-06-03	NCT06974292
Amgen	Rocatinlimab	—	COMPLETED	2025-05-03	NCT06438263
SinoMab BioScience Ltd	SM17 for injection	—	COMPLETED	2025-03-24	NCT07103369
Qilu Pharmaceutical Co., Ltd.	QL2108 injection	—	COMPLETED	2024-11-15	NCT06614907
Sun Pharmaceutical Industries, Inc.	Ruxolitinib Topical Cream 1.5%	—	COMPLETED	2024-09-23	NCT06673654
Amgen	Rocatinlimab vial injection	—	COMPLETED	2024-08-30	NCT06268860
AbbVie	Upadacitinib (ABT-494)	—	COMPLETED	2024-08-29	NCT03646604
Lynk Pharmaceuticals Co., Ltd	LNK01004 ointment 0.3%	—	COMPLETED	2024-06-18	NCT06553287
Amgen	Rocatinlimab	—	COMPLETED	2024-05-27	NCT06214481
Jiangsu vcare pharmaceutical technology co., LTD	VC005	—	COMPLETED	2024-05-23	NCT06009094
selectION Therapeutics GmbH	si-544	—	COMPLETED	2023-11-01	NCT05383378
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018 extended-release tablet	—	COMPLETED	2023-08-28	NCT05945810
Hangzhou Yirui Pharmaceutical Technology Co., Ltd	YR001 Dose A on low body surface area	—	COMPLETED	2023-08-14	NCT05718921
Incyte Corporation	Ruxolitinib cream	—	COMPLETED	2023-08-07	NCT05034822
Qilu Pharmaceutical Co., Ltd.	QLM3003	—	COMPLETED	2023-08-05	NCT05932888
Arcutis Biotherapeutics, Inc.	ARQ-151 cream 0.15%	—	COMPLETED	2023-05-02	NCT04156191
Mabwell (Shanghai) Bioscience Co., Ltd.	Experimental drug 9MW1911	—	COMPLETED	2023-03-06	NCT05803902
Biosion, Inc.	BSI-045B	—	COMPLETED	2023-02-15	NCT05114889
Pfizer	PF-07242813	—	COMPLETED	2022-12-27	NCT04668066
Kymera Therapeutics, Inc.	KT-474	—	COMPLETED	2022-10-20	NCT04772885
OrchestratePharma GmbH	Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)	—	COMPLETED	2022-10-16	NCT05461456
Mabwell (Shanghai) Bioscience Co., Ltd.	9MW1911 Injection	—	COMPLETED	2022-07-03	NCT05170243
LEO Pharma	LEO 138559	—	COMPLETED	2022-06-28	NCT05099133
Evelo Biosciences, Inc.	EDP1867	—	COMPLETED	2022-02-28	NCT04927195
NovaCell Technology Inc.	NCP112	—	COMPLETED	2021-11-20	NCT05638165
LEO Pharma	delgocitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-10-29	NCT03826901
Akesobio Australia Pty Ltd	AK120 or placebo- Part 1- Cohort 1	—	COMPLETED	2021-10-29	NCT04256174
Evelo Biosciences, Inc.	EDP1815	—	COMPLETED	2021-10-29	NCT03733353
Novartis	CEE321	—	COMPLETED	2021-05-16	NCT04612062
RAPT Therapeutics, Inc.	RPT193	—	COMPLETED	2021-04-26	NCT04271514
Pfizer	PF-06817024	—	COMPLETED	2021-03-09	NCT02743871
LEO Pharma	LEO 138559	—	COMPLETED	2021-03-02	NCT03514511
Incyte Corporation	Ruxolitinib phosphate cream	—	COMPLETED	2020-10-07	NCT03257644
LEO Pharma	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2020-03-16	NCT03556592
Novartis	LOU064	—	COMPLETED	2020-01-27	NCT03918980
Evelo Biosciences, Inc.	Placebo oral capsule	—	COMPLETED	2020-01-03	NCT03542994
Incyte Corporation	Ruxolitinib cream	—	COMPLETED	2019-12-26	NCT03920852
KoBioLabs	KBL697	—	COMPLETED	2019-12-23	NCT04056130
AOBiome LLC	Experimental: B244	—	COMPLETED	2019-05-18	NCT03775434
Shaperon	HY209	—	COMPLETED	2019-03-21	NCT03492398
Novan, Inc.	SB414 2%	—	COMPLETED	2018-05-11	NCT03431610
EHL Bio Co., Ltd.	ADSTEM Inj. (Adult human mesenchymal stem cells)	—	COMPLETED	2017-12	NCT02888704
Pfizer	Crisaborole ointment 2%	—	COMPLETED	2017-11-27	NCT03260595
Johnson & Johnson	Part 1: CNTO 7160	—	COMPLETED	2017-03-16	NCT02345928
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2016-07	NCT02647086
Reckitt Benckiser Healthcare (UK) Limited	—	—	COMPLETED	2016-04	NCT02620293
LEO Pharma	LEO 32731 cream	—	COMPLETED	2016-03	NCT02496546
Xencor, Inc.	XmAb7195	—	COMPLETED	2015-09-21	NCT02148744
LEO Pharma	Pimecrolimus cream	—	COMPLETED	2015-07	NCT02376049
Bristol-Myers Squibb	BMS-981164	—	COMPLETED	2015-04	NCT01614756
Otsuka Pharmaceutical Co., Ltd.	0.3% OPA-15406 Ointment	—	COMPLETED	2015-02	NCT02334787
LEO Pharma	LEO 39652 cream	—	COMPLETED	2014-12	NCT02219633
LEO Pharma	LEO 39652 cream	—	COMPLETED	2014-11	NCT01850849
LEO Pharma	pimecrolimus 10 mg/g cream	—	COMPLETED	2014-09	NCT02103725
Novartis	BPR277 ointment (controlled application)	—	COMPLETED	2014-02	NCT01428297
Otsuka Pharmaceutical Development & Commercialization, Inc.	OPA-15406	—	COMPLETED	2013-12	NCT01702181
MedImmune LLC	Omalizumab	Anti-IgE [EPC]	COMPLETED	2013-06	NCT01544348
LEO Pharma	LEO 29102	—	COMPLETED	2012-11	NCT01423656
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2012-03-31	NCT01385657
Amgen	Tezepelumab	—	COMPLETED	2011-01-05	NCT00757042
LEO Pharma	LEO 29102 cream	—	COMPLETED	2010-05	NCT01005823
Sun Pharmaceutical Industries, Inc.	Tacrolimus 0.1% manufactured by Taro	—	COMPLETED	2010-02	NCT00833079
LEO Pharma	LEO 29102 cream	—	COMPLETED	2009-10	NCT00958516
LEO Pharma	LEO 29102	—	COMPLETED	2009-06	NCT00891709
Zalicus	nortriptyline HCl + loratadine	—	COMPLETED	2008-09	NCT00721331

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Atopic Dermatitis

eosinophilic phenotype (2)

Novel Atopic Dermatitis Drugs by Company (New molecular entities)

6 companies have an FDA-approved novel drug for Atopic Dermatitis.

Pfizer 1 drug

Eli Lilly 1 drug

GALDERMA LABS LP 1 drug

LEO PHARMA AS 1 drug

Merck 1 drug

Regeneron 1 drug

Reformulations (16 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.